(Q36036857)

11 August 2017

1 reference

title

Antifibrotic therapy in chronic liver disease (English)

1 reference

11 August 2017

main subject

chronic liver disease

0 references

author name string

Don C Rockey

series ordinal

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Clinical Gastroenterology and Hepatology

11 August 2017

published in

1 reference

11 August 2017

volume

3

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

95-107

1 reference

Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Reversibility of hepatic fibrosis in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Purified Rat Liver Fat-Storing Cells in Culture Divide and Contain Collagen

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

The role of Smad3 in mediating mouse hepatic stellate cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Vascular mediators in the injured liver

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Host genetic factors influence disease progression in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Inhibition of rat liver fibrogenesis through noradrenergic antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Hepatic fibrogenesis requires sympathetic neurotransmitters

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Hepatocyte growth factor gene therapy of liver cirrhosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A randomized trial of prednisolone in patients with severe alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Reversal of “Cirrhosis” in Idiopathic Haemochromatosis Following Long-term Intensive Venesection Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A prospective trial of colchicine for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Colchicine in the treatment of cirrhosis of the liver.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Silymarin Retards the Progression of Alcohol-Induced Hepatic Fibrosis in Baboons

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Treatment of chronic liver diseases with traditional Chinese medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Herbal hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Trial of penicillamine in advanced primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Methotrexate therapy for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Role of abnormal methionine metabolism in alcoholic liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Meta-analysis of propylthiouracil for alcoholic liver disease--a Cochrane Hepato-Biliary Group Review

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Peroxisome proliferator-activated receptors and hepatic stellate cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Severe liver fibrosis or cirrhosis: accuracy of US for detection--analysis of 300 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900445-8

7 January 2021

10.1016/S1542-3565(04)00445-8

Identifiers

DOI

1 reference

release_tbgeelmmuba23kusuza5bv3vd4

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tbgeelmmuba23kusuza5bv3vd4

24 November 2022

mapped directly with Wikidata item

1 reference